Sarcomas vs. pharmaceutical science

Posted by: Mary Catania -

THE RIGHT TUMOR MODELS BRING GREATER CERTAINTY TO DRUG CANDIDATE SELECTION

  undefined-2

  Join us for a 20-minute lunch & learn, followed by a Q&A session. 

  What: Live webinar, “Screening Sarcoma Drug Candidates with Certainty”

  When: June 29, 2021, 12pm – 12:30pm (PST) 

 

 

Sourcing the right tumors to support your pharmaceutical company’s sarcoma drug pipeline can often be a difficult part of preclinical development. Certis leverages more clinically relevant models — orthotopic patient-derived xenograft (O-PDX) — and advanced imaging technologies to optimize lead candidate selection, and bridge the translational gap. 

  

Discover true preclinical partnership with Certis scientists who have deep expertise in the molecular pathways, biology and treatment of sarcomas 

 

Register now

 

Upcoming Sarcomas CertiScreen 

Plus, get a sneak peek at an opportunity to join our upcoming Sarcoma CertiScreena faster, more cost-efficient path to certainty that will include 21 of our best-in-class tumor models. 

 

Certis TumorBank: Sarcoma tumor models

sarcoma-characterization

  • 63 highly characterized sarcoma tumor models 
  • 23 matched cell cultures, some with TILS 
  • Biomarkers of interest: 7 with 12q15 region amplification, CDK4 and MDM2 gene amplification detected
Back to Feed


Share This